After attending the SLEEP conference where Jazz Pharmaceuticals presented data for its Sleep assets and provided an overview of the solriamfetol TONES 5 long-term data and Xyrem pediatric data, SunTrust analyst John Boris said interest from the scientific community in solriamfetol and Xyrem was "high," and that Jazz shared a range of data for solriamfetol, which derisks the asset from a regulatory standpoint ahead of the PDUFA date of December 20. Boris maintained his in-line 2022-end solriamfetol sales at $330M, with broad formulary acceptance unlikely until 2022 and reiterated a Buy rating on the shares with a $210 price target.